Crohn’s disease doesn’t have a single trigger. It develops when a combination of genetic susceptibility, environmental exposures, and gut microbiome changes converge to set off a misdirected immune response against the lining of the digestive tract. Some of these factors lay the groundwork years before symptoms appear, while others can spark flares in someone who already has the disease.
Genetics Set the Stage
The strongest known genetic risk factor for Crohn’s is a set of mutations in the NOD2 gene, which helps immune cells recognize and respond to bacteria. Three specific mutations in this gene are strongly linked to Crohn’s but not to ulcerative colitis, the other major form of inflammatory bowel disease. Carrying one copy of a mutated NOD2 gene triples your risk. Carrying two copies, or two different mutations, raises risk roughly 23-fold.
These mutations don’t guarantee you’ll develop Crohn’s. They make the immune system less effective at managing gut bacteria, which creates vulnerability. NOD2 mutations are especially tied to disease in the ileum, the last section of the small intestine, where Crohn’s most commonly strikes. Among people with ileal Crohn’s, about 27% carry NOD2 mutations compared to roughly 13% of those with Crohn’s limited to the colon.
More than 200 other gene regions have been linked to Crohn’s risk, most involving immune regulation or the intestinal barrier. But genetics alone account for only part of the picture. Crohn’s rates have risen sharply in industrialized countries over just a few decades, far too fast to be explained by genetic change alone.
A Leaky Gut Wall Lets the Immune System Overreact
The intestinal lining is a single layer of cells backed by a mucus barrier. Together, they keep trillions of gut bacteria separated from the immune cells on the other side. When this barrier breaks down, bacteria and their byproducts leak through, and the immune system responds aggressively. In a healthy gut, the response resolves. In Crohn’s, it doesn’t.
Once barrier dysfunction takes hold, activated immune cells begin circulating locally and sometimes systemically, releasing inflammatory signaling molecules that sustain and amplify the damage. This creates a cycle: inflammation damages the barrier further, which lets more bacteria through, which drives more inflammation. Understanding this loop is key because many of the triggers below ultimately work by either weakening the barrier, disrupting the bacterial balance, or ramping up the immune response.
The Gut Microbiome Shifts Before Symptoms Start
People with newly diagnosed Crohn’s, even before any treatment, show a distinctive pattern of bacterial imbalance. A large study of treatment-naive patients found that harmful bacterial families like Enterobacteriaceae and Fusobacteriaceae were overrepresented, while protective groups like Clostridiales and Bacteroidales were depleted. This imbalance correlates strongly with disease status and appears to be present from the very beginning, not just a consequence of medication.
What causes this shift isn’t entirely clear, but it likely reflects the combined influence of diet, antibiotic exposure, and genetic factors that shape which bacteria thrive. The depleted species tend to be ones that produce short-chain fatty acids, compounds that nourish the gut lining and keep inflammation in check. Losing them weakens the same barrier that keeps the immune system from overreacting.
Ultra-Processed Foods and Diet
A large prospective study found that people in the highest quartile of ultra-processed food consumption had a 70% greater risk of developing Crohn’s compared to those eating the least. Specific categories drove much of the association: ultra-processed breads and breakfast cereals, frozen ready-to-eat meals, and processed sauces, spreads, and cheeses each independently raised risk by 11% to 18% per standard deviation increase in intake.
The concern isn’t just about nutrients. Ultra-processed foods contain emulsifiers, stabilizers, and other additives that can thin the protective mucus layer in the gut and alter the microbiome. This doesn’t mean a single processed meal causes Crohn’s, but a dietary pattern built around these foods appears to meaningfully shift risk over time, especially in someone already genetically susceptible.
Early Life Exposures
What happens in the womb and during infancy can shape Crohn’s risk years later. A systematic review and meta-analysis published in The Lancet found that prenatal antibiotic exposure nearly doubled the odds of the child developing inflammatory bowel disease (odds ratio 1.8). Prenatal tobacco smoke exposure raised risk by about 50%. Even childhood ear infections, which often lead to antibiotic prescriptions, were associated with a twofold increase in IBD risk.
Antibiotic exposure in infancy showed a trend toward increased risk as well, with an odds ratio of 1.7. The mechanism is straightforward: antibiotics wipe out developing gut bacteria during a critical window when the immune system is learning to distinguish harmless microbes from threats. Disrupting that process may set up the kind of immune misfiring that underlies Crohn’s.
Vitamin D Deficiency
Low vitamin D levels are consistently associated with higher Crohn’s risk and worse outcomes. A large study of women found that those with higher vitamin D levels had a 62% lower risk of developing Crohn’s (hazard ratio 0.38). Among people who already have the disease, blood levels above 50 nmol/L are associated with fewer surgeries and hospitalizations compared to levels below that threshold. The U.S. Institute of Medicine defines outright deficiency as below 30 nmol/L.
Vitamin D helps regulate immune function and supports the integrity of the intestinal barrier, so deficiency removes a key brake on the inflammatory process. Whether supplementation can prevent Crohn’s in at-risk individuals is still being studied, but maintaining adequate levels appears protective.
Stress Triggers Inflammation Through Gut Neurons
Stress has long been recognized as a flare trigger by patients, and research now explains the biological pathway. A study published in PNAS found that stress hormones called glucocorticoids interact directly with neurons and support cells in the gut’s own nervous system. Under chronic stress, these support cells become pro-inflammatory, while gut neurons shift toward an immature state and stop producing enzymes needed for normal gut motility.
Researchers confirmed the mechanism by genetically removing glucocorticoid receptors from gut nerve cells in mice, which made the animals immune to stress-induced intestinal inflammation. This means stress doesn’t just make Crohn’s feel worse subjectively. It activates a specific inflammatory cascade in the gut wall that can initiate or worsen a flare.
NSAIDs Can Spark Flares
Common painkillers like ibuprofen and naproxen are a well-documented flare trigger for people who already have Crohn’s. A large study found that people with IBD who used NSAIDs had a 24% higher likelihood of a flare overall. The risk was most dramatic in the first two weeks after taking an NSAID, when flare rates jumped more than sixfold compared to baseline. Risk remained elevated, though lower, for up to six months afterward.
NSAIDs work by blocking enzymes that produce inflammatory compounds, but those same enzymes also help maintain the protective mucus lining of the gut. Suppressing them can compromise the intestinal barrier in exactly the way that fuels Crohn’s inflammation. Acetaminophen does not carry this risk, which is why it’s generally the preferred painkiller for people with the disease.
A Bacterial Suspect That Remains Unproven
For over a century, researchers have investigated whether a specific bacterium called Mycobacterium avium subspecies paratuberculosis (MAP) might cause Crohn’s. MAP causes a strikingly similar intestinal disease in cattle, and it can be detected more frequently in Crohn’s patients than in the general population. In one notable experiment, MAP isolated from human Crohn’s patients was fed to healthy goats, which then developed the same kind of granulomatous intestinal inflammation seen in the disease.
Despite this, the evidence remains frustratingly inconclusive. Not all Crohn’s patients carry MAP, and antibiotic regimens targeting the organism have produced mixed results in clinical trials. It’s possible that MAP triggers Crohn’s in a subset of patients while other factors drive the disease in others. It’s also possible that MAP simply colonizes an already-inflamed gut without causing the problem. The most recent clinical trial of anti-MAP therapy showed some promise, but the field hasn’t reached consensus on whether the bacterium is a cause, a contributor, or a bystander.